The current FDA-approved drugs to treat post-traumatic stress disorder (PTSD) are often only minimally effective in clinical practice. One response is the frequent use of off-label drugs in the hope of improving the quality of life of patients impacted by PTSD. This approach often comes with adverse consequences for patients and with little improvement in their quality of life. But the treatment landscape for PTSD may change for the better with the emergence of a number of investigative agents. Join Drs. Joseph Goldberg and Roger McIntyre as they evaluate the value proposition of both current PTSD treatments and those in clinical trials.
Current and Emerging Treatments for PTSD in Women: An In-Depth Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, NYDr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Receives royalties: American Psychiatric Publishing, Cambridge University Press?
Consulting Fees: AbbVie, Alkermes, Axsome, BioXcel, Intra-Cellular Therapies, Neumora, Neurelis, Otsuka, Sage Pharmaceuticals Sunovion, SupernusReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Barry A. Fiedel, PhD, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate the inadequacies and risks associated with off-label treatments for post-traumatic stress disorder (PTSD)
- Explain the link between the pathophysiology of PTSD and the pharmacological rationale for treatment
- Demonstrate knowledge of new and emerging therapies and how they fit into the clinical management of PTSD
Target Audience
This activity has been designed to meet the educational needs of pyschiatrists and primary care physicians, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with post-traumatic stress disorder (PTSD).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until November 15, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .25 contact hours/.025 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-128-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Commercial Support
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyrightSystem Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Brian Slomovitz, MD
Robert L. Coleman, MD, FACOG, FACS
- CME/CE Broadcast Replay
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
0.75 creditsNataliya Uboha, MD, PhD
Anton P. Porsteinsson, MD
C. Brendan Montano, MD
Anton P. Porsteinsson, MD